Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGM:DAVE
NasdaqGM:DAVEConsumer Finance

Dave (DAVE) Net Profit Margin Climbs to 29.8%, Reinforcing Bullish Community Narratives

Dave (DAVE) posted a net profit margin of 29.8%, jumping from 12.9% last year, as revenue is projected to grow at 15% annually, outpacing the US market’s 10.5% average. Over the past year, earnings soared 255.6%, far exceeding the company’s already impressive five-year average of 43.4% annual growth. With high-quality earnings, improved margins, and momentum on both the revenue and profit fronts, investors are likely to zero in on these operational gains as a sign of sustained business...
NYSE:PAY
NYSE:PAYDiversified Financial

Paymentus (PAY): Margin Uptick Reinforces High-Growth Narrative, But Valuation Remains a Sticking Point

Paymentus Holdings (PAY) posted net profit margins of 5.3%, a slight uptick from last year's 5.2%. Over the past five years, earnings have surged at an impressive 57.4% annual rate, but the latest annual earnings growth of 47% fell short of this pace. Looking ahead, analysts expect earnings to grow 28.1% per year and revenue to expand 19.6% annually. Both figures outpace the broader US market, yet shares trade well above DCF-based estimates with a price-to-earnings ratio of 76.1x. See our...
NasdaqGS:TSAT
NasdaqGS:TSATTelecom

Telesat (TSAT) Losses Accelerate 54% Annually, Challenging Bullish Revenue Growth Narrative

Telesat (TSAT) remains unprofitable, with losses accelerating at an average rate of 54.1% a year over the past five years. Despite the red ink, the company’s revenue is forecast to grow 23.6% annually, outpacing the US market’s 10.5% projection. While top-line expansion is impressive, TSAT’s net profit margin has yet to improve and the company is expected to stay unprofitable for at least the next three years, putting sustained pressure on investor confidence. See our full analysis for...
TSX:EFR
TSX:EFROil and Gas

Energy Fuels (TSX:EFR): Heavy Losses Persist, High Valuation Tests Growth Narrative Ahead of Profitability

Energy Fuels (TSX:EFR) remains unprofitable, with losses having accelerated by 12.2% per year over the last five years. Shares trade at a steep Price-to-Sales Ratio of 49.9x, which is significantly higher than both the Canadian Oil and Gas industry average of 2.6x and its peer average of 14.2x. Despite recent share price volatility and dilution, consensus forecasts point to annual earnings growth of 70.14% and revenue growth of 38.8%, with profitability expected in the next three years. See...
NasdaqCM:AHCO
NasdaqCM:AHCOHealthcare

AdaptHealth (AHCO) Profitability Marks Turnaround, Challenging Bearish Valuation Narratives

AdaptHealth (AHCO) recently turned profitable, with its net profit margin shifting notably over the past year. Despite a -16.2% average annual earnings growth over the last five years, forecasts now call for earnings to grow at 23.1% per year, outpacing the broader US market’s 16%. While revenue is expected to rise 7.3% per year in the coming period, which trails the US average, high earnings quality and significant near-term profit growth are clear upside drivers for investors who see value...
NYSE:GPN
NYSE:GPNDiversified Financial

Global Payments (GPN) Net Margin Tops Expectations, Reinforcing Bullish Narratives on Profit Quality

Global Payments (GPN) posted a net profit margin of 16.2%, up from 13.8% a year ago, and earnings have grown at an impressive 24% per year over the past five years, with a standout 34.4% gain in the last year alone. While revenue and projected annual earnings are expected to grow at a slower pace than the broader US market, the company’s high earnings quality and forward profit growth continue to draw attention as shares trade below estimates of fair value and at a Price-To-Earnings ratio of...
NYSE:MED
NYSE:MEDPersonal Products

Medifast (MED) Profit Margin Plunges to 0.06%, Undermining Recovery Narratives

Medifast (MED) is facing a tough outlook, with both revenue and earnings forecast to decline sharply over the next three years. Revenue is expected to decrease by 12.5% per year, and earnings are projected to fall by 146.7% annually, following a recent year in which net profit margins slipped to just 0.06%, down from 1.1% last year. The company also recorded a one-off loss of $12.5 million in the last twelve months, adding extra pressure to already weakening earnings. In fact, average annual...
NYSE:SPIR
NYSE:SPIRProfessional Services

Spire Global (SPIR) Turns Profitable, But Forecast 70% Earnings Decline Challenges Bullish Narratives

Spire Global (SPIR) recently became profitable, with its net profit margin turning positive over the past year. Despite crossing into the black, earnings are forecast to decline sharply at an annual rate of 70% over the next three years, even as revenue is projected to grow just 2.5% per year, lagging far behind the US market average of 10.5%. For investors, this means the company is coming off a milestone of positive earnings, but expectations remain muted due to forecasts for falling...
NYSEAM:CMT
NYSEAM:CMTChemicals

Core Molding Technologies (CMT): Margin Drop Contrasts With Bold Three-Year EPS Growth Outlook

Core Molding Technologies (CMT) is aiming for a massive 46.5% annual EPS growth rate over the next three years, which easily outpaces the US market average of 16%. This outlook comes as the company posts a forecasted 6.4% revenue growth per year, lagging the US market’s 10.5% average, and a net profit margin of 3.1%, down from 4.9% a year ago. After growing earnings at 20.7% per year over the last five years, CMT enters this period with a high-quality earnings track record but faces margin...
NasdaqGS:TSHA
NasdaqGS:TSHABiotechs

Taysha Gene Therapies (TSHA): Revenue Forecast to Grow 70.5% Annually, Balancing Risks and Valuation

Taysha Gene Therapies (TSHA) remains unprofitable, but its revenue is forecast to grow rapidly by 70.5% per year, far outpacing the broader US market's expected 10.5% annual growth. Over the past five years, the company has managed to cut its losses at a 7.5% annual rate, even as it is projected to stay in the red for at least the next three years. With shares recently trading at $4.27, below an estimated fair value of $20.71, investors are weighing the promise of significant top-line growth...